Chronische Aluminium-Intoxikation bei kontinuierlicher ambulanter Peritonealdialyse: Therapie mit Deferoxamin

Autor:	Bernd Grabensee, J. Passlick, F. K. Ohnesorge, M. Wilhelm, Th. Busch
Rok vydání:	2008
Předmět:	Every other day Osteomalacia business.industry medicine.medical_treatment Continuous ambulatory peritoneal dialysis General Medicine medicine.disease Peritoneal dialysis Deferoxamine Normochromic anaemia Anesthesia medicine Aluminum - blood medicine.symptom business Myopathy medicine.drug
Zdroj:	DMW - Deutsche Medizinische Wochenschrift. 114:253-257
ISSN:	1439-4413 0012-0472
DOI:	10.1055/s-2008-1066584
Popis:	After six years of home haemodialysis and two years of continuous ambulatory peritoneal dialysis a 59-year-old woman developed an aluminium-induced osteopathy, myopathy and normochromic anaemia. She was at first treated with intravenous, then peritoneal, deferoxamine, 1 g every other day. Before treatment, 15.8 micrograms aluminium (Al) had been eliminated daily, with a peritoneal clearance of 0.3 ml/min; after intravenous deferoxamine a mean of 774.3 +/- 102.3 micrograms Al was eliminated per day, after peritoneal deferoxamine 646.7 +/- 89.6 micrograms of Al per day, with a peritoneal clearance of 2.2 +/- 0.9 (intravenous) and 1.9 +/- 0.7 ml/min (intraperitoneal). After four months of deferoxamine administration, mostly intraperitoneally as an out-patient, the osteomalacia clearly improved, as did the myopathy and anaemia.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::e09b7fb19e461953b59ae2ed49df4b08 https://doi.org/10.1055/s-2008-1066584 Zobrazit plný text záznamu